Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effects of atezolizumab on select cancer types in people
whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This
study aims to determine if the information from the cancer genome analysis corresponds with
the effects of atezolizumab on individuals and their cancer.
This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is
completed, and will involve approximately 200 participants. Participants are assigned to one
of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary
unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants
in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the
first stage for each cohort, 8 participants will be enrolled and if no participants respond
to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to
treatment, up to 16 additional participants will be enrolled to that cohort. Participants
continue on treatment until they no longer may benefit from the treatment or they decide to
stop treatment.